Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Merestinib + Ramucirumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Merestinib | LY2801653|LY-2801653 | AXL Inhibitor 30 DDR1 Inhibitor 10 DDR2 inhibitor 7 FLT3 Inhibitor 69 MET Inhibitor 59 PDGFR-alpha Inhibitor 10 RON Inhibitor 11 ROS1 Inhibitor 22 Trk Receptor Inhibitor (Pan) 33 TYRO3 Inhibitor 7 | Merestinib (LY2801653) inhibits several receptor tyrosine kinases including MET, MST1R (RON), AXL, MERTK, TYRO3, ROS1 fusions, PDGFRA, FLT3, TEK, DDR1/2, MKNK1/2, and NTRK1/2/3, potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (PMID: 23275061, PMID: 29568395, PMID: 32537847). | |
Ramucirumab | Cyramza | LY3009806 | VEGFR2 Antibody 4 | Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02745769 | Phase I | Merestinib + Ramucirumab Abemaciclib + Ramucirumab | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | Completed | USA | GBR | FRA | 0 |